Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 327 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR How a Simple Tool Is Saving Lives of Children with Cancer... February 15, 2024 Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients... December 12, 2025 Heartburn Medications Pulled From Shelves Because They May Cause Cancer January 13, 2020 Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer November 5, 2019 Load more HOT NEWS Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients... The Impact of COVID-19 on Black and Hispanic People with Cancer:... Initial Results of the CanScreen5, an Authentic Data Repository for Cancer... CVS, Walgreens, Rite Aid Suspend Sales Of Zantac Following Cancer-Causing Concerns
